Tethis is developing liquid biopsy solutions based on an integrated analytical process that combines the See.d® blood sample preparation instrument, SmartBioSurface® slides treated with biocompatible nanomaterials, and AI algorithms to identify cellular elements of tumor origin. The company is led by CEO Holger Neecke and is based in Milan, Italy. It raised €15M in a new funding round to accelerate development, validation and preparation for commercialization of its diagnostic platform. The platform work centers on non-invasive blood tests that detect traces of tumor circulating in the blood. Prior investors include Genextra and Indaco Venture Partners.

Total raised

$17M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2025